LS9

LS9, Inc. Secures $15 Million in Series B Funding

LS9, Inc. Secures $15 Million in Series B Funding

October 8, 2007

Funding By Lightspeed Venture Partners, Flagship Ventures and Khosla Ventures

LS9, Inc., the Renewable Petroleum Company™, announces the close of its second round of funding with $15 million in new investments. Leading the financing was Lightspeed Venture Partners, with additional contributions from existing partners Flagship Ventures and Khosla Ventures. The funding will support the company’s continued talent acquisition and rapid commercialization of DesignerBiofuels™ products.

VisEn Medical, Inc.

VisEn Medical Raises $7 Million in Series B Financing

VisEn Medical Raises $7 Million in Series B Financing

October 23, 2007

Merck Capital Joins Flagship Ventures Backing Leader in Fluorescence In Vivo Imaging

Acceleron Pharma, Inc.

Acceleron Pharma Completes $31M Series C Financing

Acceleron Pharma Completes $31M Series C Financing

October 30, 2007

Top venture syndicate invests to advance expanding pipeline of products that modulate tissue growth and repair

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Appoints David Johnston as Chief Financial Officer

AVEO Pharmaceuticals Appoints David Johnston as Chief Financial Officer

November 1, 2007

CAMBRIDGE, MA, November 1, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of David Johnston to the newly created position of Chief Financial Officer.

Ensemble Therapeutics Corporation

Ensemble Discovery Announces Additions to its Scientific Advisory Board

Ensemble Discovery Announces Additions to its Scientific Advisory Board

November 7, 2007

Adds four distinguished scientists to its world-class SAB

CAMBRIDGE, MA (November 7, 2007) -- Ensemble Discovery Corporation, a biotechnology company developing novel classes of therapeutics and diagnostics using its proprietary DNA Programmed Chemistry™ (DPC™) platform, today announced the appointment of Francis Barany, Ph.D., Simon Campbell CBE, FMedSci, FRS, Gerard Evan, Ph.D., FRS, and Mark Murcko, Ph.D. to its Scientific Advisory Board.

Novomer, Inc.

Novomer, Next-Generation Eco-Plastics Company, Secures Series A Financing from Physic Ventures and Flagship Ventures

Novomer, Next-Generation Eco-Plastics Company, Secures Series A Financing from Physic Ventures and Flagship Ventures

November 7, 2007

Company Raises $6.6 Million to Drive Product Development and Bring Novel Eco-Plastics – Constructed from Renewable Resources – to Market

ITHACA, N.Y. – November 7, 2007 – Novomer Inc., a materials company pioneering a family of high-performance, biodegradable plastics, polymers and other chemicals from renewable substances such as carbon dioxide, today announced that it has raised $6.6 million in series A funding. Physic Ventures co-led the financing in partnership with Flagship Ventures.

Mascoma Corporation

Mascoma Corporation Acquires Celsys BioFuels, Inc.

Mascoma Corporation Acquires Celsys BioFuels, Inc.

November 7, 2007

Dr. Michael Ladisch joins as Chief Technology Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mascoma Corporation, a leader in advanced low-carbon biofuels, today announced the acquisition of Celsys BioFuels, Inc. Terms of the transaction were not disclosed.

BIND Therapeutics, Inc.

BIND Biosciences, Inc. Closes $16M Series B Financing Round

BIND Biosciences, Inc. Closes $16M Series B Financing Round

November 27, 2007

CAMBRIDGE, MA – November 27, 2007 – BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing “smart” therapeutic targeted nanoparticles capable of differential delivery and controlled drug release to diseased tissue, announced today that it has secured a $16 million Series B financing. BIND’s platform is based on a combinatorial technology that allows for precise engineering of optimally formulated targeted nanoparticles that substantially increase the clinical efficacy and safety of existing and new therapeutics.

LS9

LS9, the Renewable Petroleum Company, Selected by World Economic Forum as 2008 Technology Pioneer

LS9, the Renewable Petroleum Company, Selected by World Economic Forum as 2008 Technology Pioneer

November 29, 2007

President of pioneering hydrocarbon biofuels company to accept honor in Davos, Switzerland

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project

AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project

December 4, 2007

Agreement Highlights Growing Interest in Novel Biology Platform that Identifies Clinical Response of Cancer Drugs